/Vertex%20Pharmaceuticals%2C%20Inc_%20logo%20and%20data-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
With a market cap of $122.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) operates as a global biotechnology company that develops and commercializes therapies for treating cystic fibrosis (CF). The Boston, Massachusetts-based company is expected to release its Q1 2025 earnings after the market closes on Monday, May 5.
Ahead of this event, analysts expect VRTX to post adjusted earnings of $3.69 per share, down a staggering 14% from $4.29 per share reported in the same quarter last year. On a positive note, the company has surpassed Wall Street's bottom-line estimates in three of the past four quarters, but has missed the projections on one other occasion. In the previous quarter, its adjusted EPS of $3.54 surpassed the consensus estimates by 4.7%.